Hälsa & medicin
4.1
Diabetes Drug Dulaglutide Linked to Heart Protection Through Specific Blood Markers
Researchers identified specific biomarkers that predict which diabetes patients will benefit most from dulaglutide in preventing heart attacks and strokes. The finding could help clinicians target the expensive GLP-1 drug to patients most likely to respond, potentially improving treatment outcomes and reducing healthcare costs.
Originaltitel: Biomarker Changes Associated With Both Dulaglutide and Cardiovascular Events in the REWIND Randomized Controlled Trial: A Nested Case-Control Post Hoc Analysis